Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 5/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 2/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16571113 | 0.82 | PTK2 (0.44) | AURKAGRIN2BPTK2GAA | |
| SCHEMBL16332608 | 0.79 | KIF11 (0.46) | KIF11AURKAGRIN2BCTSCGRIN1 | |
| SCHEMBL16570655 | 0.77 | PTK2 (0.43) | PTK2NAMPT | |
| SCHEMBL16570980 | 0.77 | PTK2 (0.71) | PTK2GAA | |
| SCHEMBL16570521 | 0.76 | PTK2 (0.41) | AURKAGRIN2BPTK2NAMPT | |
| SCHEMBL16570201 | 0.74 | KIF11 (0.47) | KIF11PTK2 | |
| SCHEMBL10558040 | 0.69 | KIF11 (0.62) | KIF11KDM4ENAMPT | |
| SCHEMBL1607822 | 0.68 | HDAC2 (0.47) | GRIN2BPTK2 | |
| SCHEMBL3267001 | 0.67 | KIF11 (0.51) | KIF11AURKACTSCNAMPT | |
| SCHEMBL10417635 | 0.67 | KIF11 (0.60) | KIF11AURKACTSCKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | KIF11 3206/4885AURKA 812/4885GRIN2B 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.